将传统合成改善病情抗风湿药减量至无药缓解与稳定治疗对类风湿关节炎的影响(ARCTIC REWIND):一项开放标签、随机对照、非劣效性试验的3年结果
ARCTIC REWIND试验纳入160例持续缓解至少1年的类风湿关节炎患者,随机分为稳定剂量、半剂量、半剂量1年后停药三组,比较3年复发风险。稳定剂量组无复发生存率80%,半剂量组57%,减量至停药组38%,非劣效性未成立。
要点
- 稳定剂量组3年无复发生存率80%,半剂量组57%,减量至停药组38%。
- 与稳定剂量相比,半剂量组复发风险差23%,减量至停药组40%,非劣效性未成立。
- 无药缓解在部分患者中可实现,但两种减量策略的复发风险均显著高于稳定治疗。
核心结论
- 两种传统合成DMARD减量策略与稳定治疗相比,无复发生存率显著降低,数据不支持非劣效性。
- 无药缓解在相当一部分患者中可实现。
- 该试验为不同治疗策略的风险与获益提供了信息,有助于医患共同决策。
研究设计与样本
- 开放标签、随机对照、非劣效性试验,纳入年龄18-80岁、持续缓解至少1年且稳定使用传统合成DMARD的类风湿关节炎患者。
- 来自挪威十家医院,按中心分层随机(2:1:1)分为稳定剂量组(n=80)、半剂量组(n=42)、半剂量1年后停药组(n=38)。
- 主要终点为3年内疾病复发,分析无复发生存率和风险差,非劣效性界值为20%,在意向治疗人群中进行符合方案分析。
- 156例接受分配治疗,155例纳入符合方案分析;139例完成3年随访。
- 试验注册号ClinicalTrials.gov NCT01881308,已完成。
主要发现
- 3年研究期间,稳定剂量组无复发比例为80%(95%CI 69-88%),半剂量组为57%(41-71%),减量至停药组为38%(22-53%)。
- 与稳定剂量组相比,半剂量组复发风险差为23%(95%CI 6-41%,p=0.010),减量至停药组为40%(22-58%,p<0.0001),非劣效性未成立。
- 不良事件发生率:稳定剂量组65/78(83%),半剂量组36/40(90%),减量至停药组36/37(97%)。
- 稳定剂量组发生1例死亡(猝死,认为与研究药物不太可能相关)。
- 156例患者中女性104例(67%),男性52例(33%)。
临床怎么用
- 原文结论未据此给出具体推荐,仅指出该试验为不同治疗策略的风险与获益提供了信息,有助于医患共同决策。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tapering of disease-modifying antirheumatic drugs (DMARDs) to drug-free remission is an attractive treatment goal for patients with rheumatoid arthritis, although long-term effects of tapering and withdrawal remain unclear. We compared 3-year risks of flare between three conventional synthetic DMARD treatment strategies in patients with rheumatoid arthritis in sustained remission. METHODS: In this open-label, randomised controlled, non-inferiority trial, we enrolled patients aged 18-80 years with rheumatoid arthritis who had been in sustained remission for at least 1 year on stable conventional synthetic DMARD therapy. Patients from ten hospitals in Norway were randomly assigned (2:1:1) with centre stratification to receive stable conventional synthetic DMARDs, half-dose conventional synthetic DMARDs, or half-dose conventional synthetic DMARDs for 1 year followed by withdrawal of all conventional synthetic DMARDs. The primary endpoint of this part of the study was disease flare over 3 years, analysed as flare-free survival and risk difference in the per-protocol population with a non-inferiority margin of 20%. This trial is registered with ClinicalTrials.gov (NCT01881308) and is completed. FINDINGS: Between June 17, 2013, and June 18, 2018, 160 patients were enrolled and randomly assigned to receive stable-dose conventional synthetic DMARDs (n=80), half-dose conventional synthetic DMARDs (n=42), or half-dose conventional synthetic DMARDs tapering to withdrawal (n=38). Four patients did not receive the intervention and 156 patients received the allocated treatment strategy. One patient was excluded due to major protocol violation and 155 patients were included in the per-protocol analysis. 104 (67%) of 156 patients were women and 52 (33%) were men. 139 patients completed 3-years follow-up without major protocol violation; 68 (87%) of 78 patients in the stable-dose group, 36 (88%) of 41 patients in the half-dose group and 35 (95%) of 37 patients in the half-dose tapering to withdrawal group. During the 3-year study period, 80% (95% CI 69-88%) were flare-free in the stable-dose group, compared with 57% (41-71%) in the half-dose group and 38% (22-53%) in the half-dose tapering to withdrawal group. Compared with stable-dose conventional synthetic DMARDs, the risk difference of flare was 23% (95% CI 6-41%, p=0·010) in the half-dose group and 40% (22-58%, p<0·0001) in the half-dose tapering to withdrawal group, non-inferiority was therefore not shown. Adverse events were reported in 65 (83%) of 78 patients in the stable-dose group, 36 (90%) of 40 patients in the half-dose group, and 36 (97%) of 37 patients in the half-dose tapering to withdrawal group. One death occurred in the stable-dose conventional synthetic DMARD group (sudden death considered unlikely related to the study medication). INTERPRETATION: Two conventional synthetic DMARD tapering strategies were associated with significantly lower rates of flare-free survival compared with stable conventional synthetic DMARD treatment, and the data do not support non-inferiority. However, drug-free remission was achiveable for a significant subgroup of patients. This trial provides information on risk and benefits of different treatment strategies important for shared decision making. FUNDING: Research Council of Norway and South-Eastern Norway Regional Health Authority.
引用
- Kjørholt KE, Sundlisæter NP, Aga AB, et al. Effects of tapering conventional synthetic disease-modifying antirheumatic drugs to drug-free remission versus stable treatment in rheumatoid arthritis (ARCTIC REWIND): 3-year results from an open-label, randomised controlled, non-inferiority trial. Lancet Rheumatol. 2024. PMID: 38583450. doi:10.1016/S2665-9913(24)00021-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。